Concepedia

Author

Abhilash Venugopalan

Center for Cancer ResearchORCID

Also Known As

A. Venugopalan, Abhilash Karavattu Venugopalan, Abhilash Venugopalan

57

Publications

629

Citations

10

H-Index

16

Concepts

All Affiliations

Center for Cancer ResearchNational Cancer InstituteNational Institutes of HealthNational Center for Biotechnology InformationWalter Reed National Military Medical Center
AV

About

Abhilash Venugopalan is an author at Center for Cancer Research specializing in lung cancer, tumor biology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

97

2

Cell Biology

2

2

97

3

Immunology

1

1

50

4

Pathology

1

1

50

5

Cancer Therapeutics

1

1

50

Abhilash Venugopalan

×

11

Publications

610

Citations

10

H-Index

YearCitations

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer

Nitin Roper, Anna‐Leigh Brown, Jun S. Wei,

Cell Reports Medicine

2020

167

APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors

Nitin Roper, Shaojian Gao, Tapan K. Maity,

Cell Reports

2019

106

Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor–Driven Lung Adenocarcinoma

Tapan K. Maity, Abhilash Venugopalan, Ilona Linnoila,

Cancer Discovery

2015

73

Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response

Xu Zhang, Tapan K. Maity, Manoj Kumar Kashyap,

Molecular & Cellular Proteomics

2017

55

EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models

Abhilash Venugopalan, Min-Jung Lee, Gang Niu,

Oncotarget

2016

50

Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics

Xu Zhang, Natalya Belkina, Harrys K.C. Jacob,

PROTEOMICS

2014

47

Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors

Sakshi Tomar, Jingli Zhang, Manakamana Khanal,

Molecular Cancer Therapeutics

2022

45

Genomic profiling of multiple sequentially acquired tumor metastatic sites from an “exceptional responder” lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response

Romi Biswas, Shaojian Gao, Constance M. Cultraro,

Molecular Case Studies

2016

24

Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V

Xu Zhang, Khoa Dang P. Nguyen, Paul A. Rudnick,

Molecular & Cellular Proteomics

2019

21

SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma

Abhilash Venugopalan, Matthew Lynberg, Constance M. Cultraro,

Oncogene

2021

12

Page 1